The use of fibrinogen concentrate in coagulation testing aids in the diagnosis and management of rare bleeding disorders

BACKGROUND: Many clinical laboratories lack the methods or resources to quickly identify rare haemorrhagic diseases, such as genetic/acquired fibrinogen defects and factor XIII deficiency. CASE REPORT: This report explored the value of human fibrinogen concentrate in the diagnosis and management of rare bleeding disorders through three case studies. Case 1 involved acquired hypofibrinogenemia caused by snake bite, where the coagulation abnormality was corrected by adding fibrinogen in vitro, confirming the mechanism of snake venom-specific degradation of fibrinogen. Case 2 utilised fibrinogen solution to establish a thromboelastography mixing test for rapid diagnosis of autoimmune factor XIII inhibitors. Case 3 improved platelet aggregation function in patients with congenital abnormal fibrinogenaemia through fibrinogen solution. CONCLUSION: These case studies showed that fibrinogen concentrate may serve as a specific additive to assist in the rapid identification of coagulation dysfunction and guide precise treatment.